(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.71%
2.23% $ 64.06
@ $64.15
Ausgestellt: 26 Apr 2024 @ 19:48
Rendite: -0.14%
Vorheriges Signal: Apr 25 - 21:50
Vorheriges Signal:
Rendite: 2.40 %
Live Chart Being Loaded With Signals
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide...
Stats | |
---|---|
Tagesvolumen | 946 213 |
Durchschnittsvolumen | 1.09M |
Marktkapitalisierung | 10.07B |
EPS | $0 ( 2024-02-01 ) |
Nächstes Ertragsdatum | ( $0.460 ) 2024-05-01 |
Last Dividend | $0.0800 ( 2023-11-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 46.09 |
ATR14 | $1.869 (2.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Bohnen Shane | Sell | 2 259 | Restricted Stock Units |
2024-04-03 | Bohnen Shane | Buy | 2 259 | Common Stock |
2024-04-03 | Bohnen Shane | Sell | 747 | Common Stock |
2024-03-07 | Nusse Roeland | Sell | 10 400 | Common Stock |
2024-02-01 | Geist William | Sell | 1 111 | Common Stock |
INSIDER POWER |
---|
3.64 |
Last 99 transactions |
Buy: 1 979 464 | Sell: 2 067 622 |
Volumen Korrelation
Bio-Techne Corp Korrelation
10 Am meisten negativ korreliert | |
---|---|
SVAC | -0.935 |
TLGT | -0.901 |
RMRM | -0.897 |
PAIC | -0.887 |
FEYE | -0.864 |
SVOK | -0.851 |
TEAM | -0.842 |
UBOH | -0.834 |
TRIN | -0.833 |
INZY | -0.827 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Bio-Techne Corp Korrelation - Währung/Rohstoff
Bio-Techne Corp Finanzdaten
Annual | 2023 |
Umsatz: | $1.14B |
Bruttogewinn: | $769.82M (67.72 %) |
EPS: | $1.810 |
FY | 2023 |
Umsatz: | $1.14B |
Bruttogewinn: | $769.82M (67.72 %) |
EPS: | $1.810 |
FY | 2022 |
Umsatz: | $1.11B |
Bruttogewinn: | $756.50M (68.42 %) |
EPS: | $1.730 |
FY | 2021 |
Umsatz: | $931.03M |
Bruttogewinn: | $632.85M (67.97 %) |
EPS: | $0.867 |
Financial Reports:
No articles found.
Bio-Techne Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0625 | 2008-10-30 |
Last Dividend | $0.0800 | 2023-11-09 |
Next Dividend | $0 | N/A |
Payout Date | 2023-11-24 | |
Next Payout Date | N/A | |
# dividends | 61 | -- |
Total Paid Out | $4.63 | -- |
Avg. Dividend % Per Year | 0.25% | -- |
Score | 4.89 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.04 | |
Div. Directional Score | 8.94 | -- |
Year | Amount | Yield |
---|---|---|
2008 | $0.0625 | 0.37% |
2009 | $0.253 | 1.57% |
2010 | $0.263 | 1.53% |
2011 | $0.273 | 1.64% |
2012 | $0.285 | 1.66% |
2013 | $0.303 | 1.75% |
2014 | $0.313 | 1.33% |
2015 | $0.320 | 1.40% |
2016 | $0.320 | 1.45% |
2017 | $0.320 | 1.25% |
2018 | $0.320 | 0.97% |
2019 | $0.320 | 0.90% |
2020 | $0.320 | 0.58% |
2021 | $0.320 | 0.41% |
2022 | $0.320 | 0.26% |
2023 | $0.320 | 0.39% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.196 | 1.500 | 6.08 | 9.13 | [0 - 0.5] |
returnOnAssetsTTM | 0.0821 | 1.200 | 7.26 | 8.72 | [0 - 0.3] |
returnOnEquityTTM | 0.115 | 1.500 | 9.84 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.225 | -1.000 | 7.75 | -7.75 | [0 - 1] |
currentRatioTTM | 4.37 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.54 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.962 | 1.500 | 5.77 | 8.65 | [0.2 - 2] |
debtRatioTTM | 0.203 | -1.500 | 6.61 | -9.91 | [0 - 0.6] |
interestCoverageTTM | 20.76 | 1.000 | 3.42 | 3.42 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.755 | 2.00 | 9.42 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.431 | 2.00 | 9.28 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.283 | -1.500 | 8.87 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.671 | 1.000 | 2.15 | 2.15 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.235 | 1.000 | 7.31 | 7.31 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.497 | 1.000 | 8.35 | 8.35 | [0.2 - 2] |
assetTurnoverTTM | 0.419 | 0.800 | -0.538 | -0.430 | [0.5 - 2] |
Total Score | 11.84 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 45.02 | 1.000 | 5.55 | 0 | [1 - 100] |
returnOnEquityTTM | 0.115 | 2.50 | 9.90 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.431 | 2.00 | 9.52 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.500 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.755 | 2.00 | 9.42 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.225 | 1.500 | 7.75 | -7.75 | [0 - 1] |
pegRatioTTM | 0.335 | 1.500 | -1.100 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.241 | 1.000 | 6.46 | 0 | [0.1 - 0.5] |
Total Score | 6.04 |
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.